ImmunityBio, Inc.
IBRX
$8.73
$0.526.27%
NASDAQ
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 696.21% | 1,050.02% | 4,383.61% | 10,051.99% | 2,181.35% |
| Total Other Revenue | -48.57% | 64.69% | 60.38% | 86.42% | 127.10% |
| Total Revenue | 668.31% | 1,025.95% | 4,227.22% | 10,238.41% | 2,270.58% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 663.21% | 1,020.89% | 4,212.39% | 10,219.21% | 2,270.58% |
| SG&A Expenses | -11.09% | -7.09% | -5.06% | 10.57% | 24.60% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.89% | -6.36% | -5.13% | -0.19% | -0.84% |
| Operating Income | 25.61% | 27.43% | 20.55% | 9.15% | 4.75% |
| Income Before Tax | 15.00% | 40.69% | 38.59% | 31.93% | 29.16% |
| Income Tax Expenses | -- | 100.00% | 187.50% | -485.00% | -- |
| Earnings from Continuing Operations | 15.03% | 40.69% | 38.58% | 31.96% | 29.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -8.64% | -10.47% | -35.77% | -81.69% | -87.65% |
| Net Income | 15.03% | 40.69% | 38.58% | 31.93% | 29.09% |
| EBIT | 25.61% | 27.43% | 20.55% | 9.15% | 4.75% |
| EBITDA | 26.34% | 28.23% | 21.11% | 9.19% | 4.73% |
| EPS Basic | 34.94% | 52.95% | 50.82% | 47.69% | 46.85% |
| Normalized Basic EPS | 34.85% | 52.87% | 50.74% | 47.55% | 46.70% |
| EPS Diluted | 38.67% | 52.96% | 47.67% | 44.56% | 43.83% |
| Normalized Diluted EPS | 34.80% | 52.87% | 50.79% | 47.59% | 46.74% |
| Average Basic Shares Outstanding | 31.87% | 25.54% | 25.43% | 30.33% | 37.13% |
| Average Diluted Shares Outstanding | 31.71% | 25.49% | 25.56% | 30.48% | 37.30% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |